Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/174574
Title: Cost-effectiveness of direct oral anticoagulants versus vitamin K antagonist in atrial fibrillation: A study protocol using Real-World Data from Catalonia (FantasTIC Study)
Author: Hernández Rojas, Zojaina
Dalmau Llorca, Maria Rosa
Aguilar Martín, Carina
Gonçalves, Alessandra Queiroga
Casajuana, Marc
Fernández Sáez, José
Rodríguez Cumplido, Dolores
Forcadell Drago, Emma
Carrasco Querol, Noèlia
Pepió i Vilaubí, Josep M.
Alegret, Josep M.
Keywords: Cost de l'assistència sanitària
Catalunya
Assaigs clínics
Anticoagulants (Medicina)
Vitamines K
Cost of medical care
Catalonia
Clinical trials
Anticoagulants (Medicine)
Vitamin K
Issue Date: 4-Sep-2020
Publisher: Ovid Technologies (Wolters Kluwer Health)
Abstract: Background: Anticoagulant therapy is used for stroke prevention and proved to be effective and safe in the long term. The study aims to analyse the cost-effectiveness relationship of using of direct-acting oral anticoagulants vs vitamin K antagonists to prevent ischaemic stroke in patients with nonvalvular atrial fibrillation, including all the active ingredients marketed in Spain, prescribed for 2 years in the Primary Care service of the Institut Català de la Salut. Methods: Population-based cohort study, in which the cost of the 2 treatment groups will be evaluated. Direct costs (pharmacy, primary care, emergency and hospitalization) and indirect costs (lost productivity) will be included from a social perspective. Effectiveness (assessed as the occurrence of a health event, the 1 of primary interest being stroke) will be determined, with a 2-year time horizon and a 3% discount rate. The average cost of the 2 groups of drugs will be compared using a regression model to determine the factors with the greatest influence on determining costs. We will carry out a univariate ('one-way') deterministic sensitivity analysis. Discussion: We hope to provide relevant information about direct and indirect costs of oral anticoagulants, which, together with aspects of effectiveness and safety, could help shape the consensual decision-making of evaluating bodies.
Note: Reproducció del document publicat a: https://doi.org/10.1097/MD.0000000000022054
It is part of: Medicine, 2020, vol. 99 (36), num. e22054
URI: http://hdl.handle.net/2445/174574
Related resource: https://doi.org/10.1097/MD.0000000000022054
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
Cost_effectiveness_of_direct_oral_anticoagulants.79.pdf281.63 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons